The elephant in the room is that since our patents have been invalidated Vasepa's IP is completely exposed and generics will benefit if we pursue and promote any use of Vascepa incl covid19. If generics get a whiff of any potential use for covid they will dig their heels in and take all prescriptions regardless of the indication.
Catch 22 for Amarin. There has to be a pathway to settle this thing sooner rather than waiting for 2nd or 3rd qtr 2021 for appeal judgement. Of which our chance of winning is a coin flip.
Where is the FDA in all this fiasco? They need to step up somehow to protect drug innovation by taking a stand to protect a mult-use drug like Vascepa.
Forgot who was told by IR that amrn was trying to get their ducks in a row before the CC. But MF JT didn’t share anything about this during CC, instead claiming shareholder support his idiotic GIA. I know there were gia boys before, but doubt any left by now.
News 
Market Data 
Discover 
